Latest news with #Drugmaker
Bloomberg
21-07-2025
- Business
- Bloomberg
Sarepta Is Worth $0 Amid ‘Unwinnable' FDA Fight, Analyst Says
Shares of Sarepta Therapeutics Inc. have zero value following the recent back-and-forth between the drugmaker and US regulators that could lead to a market withdrawal of its Elevidys treatment, according to analysts at HC Wainwright & Co. LLC. Analysts led by Mitchell S. Kapoor on Monday slashed their price target on the stock to $0 — a rare move — from $10, while maintaining a sell recommendation. The cut comes as the drugmaker refused to voluntarily pause shipments of its lead therapy following a request by the US Food and Drug Administration after three deaths were linked to the company's gene therapies.
Reuters
21-07-2025
- Business
- Reuters
Biogen to invest $2 billion more in North Carolina
July 21 (Reuters) - Drugmaker Biogen (BIIB.O), opens new tab said on Monday it will invest an additional $2 billion in its existing manufacturing footprint in North Carolina's Research Triangle Park. The company has invested about $10 billion in its North Carolina manufacturing to date.
